What You Should Know:
– Neurogen Biomarking announced a strategic partnership with NeuroX, a venture of American TelePhysicians, to integrate specialized virtual neurology services into its brain healthcare ecosystem.
– The collaboration aims to significantly accelerate the early detection of Alzheimer’s disease (AD) and Mild Cognitive Impairment (MCI) by providing patients with timely access to expert neurological guidance via telehealth.
Reimagining Early Alzheimer’s Detection Amidst Growing Need
The current healthcare landscape presents significant challenges for timely AD diagnosis. “The current standard of care for Alzheimer’s disease is inefficient and delays diagnosis of AD by years,” stated Dr. Rany Aburashed, Chief Executive Officer and Founder of Neurogen Biomarking. Factors contributing to this include long waits to see specialists and a looming neurologist shortage, with the American Academy of Neurology (AAN) projecting a 19% supply gap by 2025. This diagnostic delay occurs against a backdrop of significant need: an estimated 7 million Americans aged 65+ lived with Alzheimer’s dementia in 2024, and while roughly 16 million experience memory impairment (potentially MCI), a staggering 92% of MCI cases remain undiagnosed.
Neurogen’s platform is pioneering a patient-initiated approach, combining innovative blood biomarker testing with AI-enhanced digital cognitive assessments. The addition of NeuroX’s board-certified neurologists promises to streamline the patient journey, offering expert support and follow-up care within weeks, a stark contrast to the months-long wait times often encountered in traditional neurology settings.
How the Integrated Platform Works: A Patient-Centered Journey
Neurogen’s ecosystem offers a streamlined, patient-initiated path for individuals with memory or thinking concerns:
- Digital Cognitive Assessment: The journey begins online with advanced assessments from collaborator Linus Health to identify individuals at higher risk and determine eligibility for further steps.
- At-Home Biomarker Testing: Eligible patients receive an at-home blood collection kit. A phlebotomist guides the collection process in the patient’s home.
- Advanced Lab Analysis: The sample is sent to a certified lab for analysis measuring ptau217, a specific blood biomarker for AD pathology, utilizing ultrasensitive detection technology (supported by collaborator Quanterix Corporation).
- Expert Virtual Neurologist Guidance (NeuroX): NeuroX’s board-certified telehealth neurologists guide patients through their results and next steps, providing:
- Blood Biomarker Test Interpretation: Explaining the nuances of elevated ptau217 results and guiding appropriate healthcare navigation.
- Personalized Brain Health Report: Translating complex cognitive assessment outcomes into easy-to-understand language.
- Personalized Brain Health Action Plan: Offering actionable lifestyle recommendations (exercise, diet, sleep) to support cognitive health.
Availability
The integrated Neurogen Biomarking platform, featuring collaborations with NeuroX, Linus Health, and Quanterix, is slated for commercial availability in 2025 for individuals with eligible memory and thinking concerns. This partnership represents a significant step towards empowering individuals with earlier, more accessible, and actionable insights into their cognitive health, potentially transforming outcomes for millions affected by or at risk for Alzheimer’s disease.
